 |
 |
Date Announced: 24 Sep 2013
Boston fund Camber Capital Management takes share in dental laser firm.
IRVINE, CA--(Marketwired - Sep 24, 2013) - BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, and a pioneer in laser surgery in other medical specialties, today announced that it has received a commitment from Camber Capital Management, LLC ("Camber") to purchase an aggregate of $5 million of its common stock.
Camber entered into a definitive subscription agreement with BIOLASE pursuant to which it subscribed for an aggregate of 2,688,172 shares of BIOLASE's common stock at $1.86 per share, a price equal to the closing price on September 23, 2013. The closing of the offering is expected to take place on or about September 27, 2013, subject to the satisfaction of customary closing conditions.
Northland Securities, Inc. acted as exclusive placement agent in connection with the offering.
A shelf registration statement (File No. 333-190158) relating to the shares issued in the offering has been filed with and declared effective by the Securities and Exchange Commission (the "SEC"). A prospectus supplement relating to the offering will be filed by BIOLASE with the SEC. Copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC's website at http://www.sec.gov, at request from Northland Securities, Inc. by e-mailing Andrew Pafko at apafko@northlandcapitalmarkets.com, or from BIOLASE, Inc., 4 Cromwell, Irvine, California 92618.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of BIOLASE in this offering. There shall not be any offer, solicitation of an offer to buy, or for the sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
Source: Biolase
E-mail: via web site
Web Site: www.biolase.com
| © 2024 SPIE Europe |
|
